Results 171 to 180 of about 56,231 (274)

Mind the gap!Connexins and pannexins in physiology, pharmacology and disease.

Frontiers in Pharmacology, 2013
Aida eSalameh, Stefan eDhein, Katja eBlanke   +2 more
doaj   +1 more source

The gap junction proteins beta 1-connexin (connexin-32) and beta 2-connexin (connexin-26) can form heteromeric hemichannels.

The Journal of biological chemistry, 1995
Two different types of gap junction proteins, beta 1- and beta 2-connexin, were expressed in insect cells, either singly or together, using infection with recombinant baculovirus. Membrane fractions enriched in gap junction proteins were isolated, and connexons (hemichannels) were solubilized with detergent.
openaire   +1 more source

Application Strategies of Bone Marrow Mesenchymal Stromal Cells in Bone‐Related Diseases

Cell Proliferation, Volume 59, Issue 4, April 2026.
Engineered BMSCs and vesicles enhance therapy effects for bone diseases via multi‐strategic approaches. ABSTRACT Bone‐related diseases (e.g., osteoporosis, osteoarthritis and fractures) exhibit a rising global incidence, imposing significant burdens on both quality of life and healthcare systems.
Xuemei Long, Dan Tan, Qianke Tao, Qiaonan Ye, Luwen Ye, Qing Li, Jingang Xiao   +6 more
wiley   +1 more source

Connexin-43 Restoration Alleviates Desmosomal Arrhythmogenic Cardiomyopathy. [PDF]

Circ Heart Fail
Zhang J, Zanella F, Ellis MW, Bradford WH, Gutierrez-Lara EJ, Wang TM, Fujita K, Duron C, Karakikes I, Lyon RC, Mezzano V, Roberts JD, Carromeu C, Gu Y, Martin JL, Muotri AR, Scheinman MM, Peterson KL, Sheikh F.   +18 more
europepmc   +1 more source

Targeting inflammation in cardiometabolic disease: Icosapent ethyl modulates monocyte‐derived macrophages isolated from patients with cardiovascular disease with or without type 2 diabetes

Diabetic Medicine, Volume 43, Issue 4, April 2026.
Abstract Aims Despite intensive lipid‐lowering therapy, individuals with atherosclerotic cardiovascular disease (ASCVD) exhibit residual inflammatory risk, which drives recurrent cardiovascular events. This risk is amplified in type 2 diabetes mellitus (T2DM), where a pro‐inflammatory milieu accelerates atherogenesis. Monocyte‐derived macrophages (MDMs)
J. K. Ward, M. U. Shah, K. Lee, P. E. Squires, C. E. Hills   +4 more
wiley   +1 more source

Effectiveness of warm acupuncture and moxibustion in the treatment of osteoarthritis: a retrospective study on clinical and molecular outcomes. [PDF]

Front Med (Lausanne)
Zhou J, Li K, Yang Y, Lu L.
europepmc   +1 more source

Molecular Markers Distinguishing Early‐Stage Mycosis Fungoides From Atopic Dermatitis Skin Lesions

Experimental Dermatology, Volume 35, Issue 4, April 2026.
ABSTRACT Mycosis fungoides (MF) is the most common type of primary cutaneous T‐cell lymphoma, a disease characterized by malignant T cells that home to the skin. In early stages, clinical presentation is often indistinguishable from benign chronic inflammatory skin diseases such as atopic dermatitis (AD), posing a challenge for proper diagnosis and ...
Brandon D. Ng, Conor Whelan, Natalia Alkon, Agata Kurowski, Constanze Jonak, Patrick M. Brunner   +5 more
wiley   +1 more source

Connexins in Acquired Hearing Loss: Expanding Research Perspectives. [PDF]

Biomedicines
Huang S, Zhu J, Zhang J, Gong T, Fei Z, Chen P, Hou S, Yang J.   +7 more
europepmc   +1 more source

EHD4 and ASAP2 are critical negative regulators of the claudin‐5‐based endothelial barrier

The FEBS Journal, Volume 293, Issue 7, Page 2067-2085, April 2026.
Cell‐surface CLDN‐5 protein levels can be evaluated using a probe that can bind to the extracellular domains of CLDN‐5. A probe derived from Clostridium perfringens enterotoxin allows us to isolate cells with high CLDN‐5 protein levels from a knockout cell library.
Yosuke Hashimoto, Gergő Porkoláb, Natalie Hudson, Jeffrey O'Callaghan, Nicole Hanley, Conor Delaney, Mária A. Deli, Peter Westenskow, Matthew Campbell   +8 more
wiley   +1 more source

Sacubitril/Valsartan Attenuates Inflammation and Fibrosis Associated With Decreased Integrin α8 and Inhibits Hepatocarcinogenesis in a Rat Model of Metabolic Dysfunction‐Associated Steatohepatitis

Hepatology Research, Volume 56, Issue 4, Page 420-435, April 2026.
Sacubitril/Valsartan (Sac/Val) alleviates fibrosis and inflammation in metabolic dysfunction‐associated steatohepatitis (MASH). Its anti‐fibrotic effect is linked to the suppression of Integrin alpha 8 (Itga8), a protein crucial for hepatic stellate cell (HSC) activation and collagen production.
Hayato Kawamura, Aya Naiki‐Ito, Xiaochen Kuang, Akihiro Murakami, Masayuki Komura, Takanori Suzuki, Hiroyuki Kato, Yuko Nagayasu, Kentaro Matsuura, Kei Fujiwara, Hiromi Kataoka, Satoru Takahashi   +11 more
wiley   +1 more source